Octagon Capital Advisors LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 29 US equity positions worth $903.6m in its Q1 2026 13F filing. The largest position was DNTH at 18.1% of the reported book, followed by COGT and ABVX.
What did Octagon Capital Advisors LP own in Q1 2026? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 18.1% | $163.4m | 1,946,667 | – | |
| 2 | COGT COGENT BIOSCIENCES INC | Healthcare | 10.0% | $90.5m | 2,350,000 | – | |
| 3 | ABVX ABIVAX SA | Healthcare | 8.3% | $75.4m | 677,000 | – | |
| 4 | ALMS ALUMIS INC | Healthcare | 6.9% | $62.4m | 2,830,700 | – | |
| 5 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 5.1% | $46.1m | 2,440,000 | – | |
| 6 | AVBP ARRIVENT BIOPHARMA INC | Healthcare | 5.0% | $45.5m | 1,971,054 | – | |
| 7 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 4.4% | $39.6m | 8,859,911 | – | |
| 8 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.9% | $35.4m | 425,000 | – | |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 3.5% | $31.3m | 338,900 | – | |
| 10 | BIOA BIOAGE LABS INC | 3.4% | $30.6m | 1,748,000 | – | ||
| 11 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.3% | $29.8m | 750,000 | – | ||
| 12 | 4XC1 KALVISTA PHARMACEUTICALS INC | 3.2% | $29.2m | 1,450,000 | – | ||
| 13 | XENE XENON PHARMACEUTICALS INC | Healthcare | 3.2% | $28.5m | 490,000 | – | |
| 14 | 430 TERNS PHARMACEUTICALS INC | 3.1% | $27.9m | 530,000 | – | ||
| 15 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.0% | $26.8m | 3,166,600 | – | |
| 16 | PALI PALISADE BIO INC | Healthcare | 2.0% | $18.0m | 10,276,317 | – | |
| 17 | TRVI TREVI THERAPEUTICS INC | Healthcare | 2.0% | $17.7m | 1,485,000 | – | |
| 18 | IRON DISC MEDICINE INC | Healthcare | 1.9% | $17.3m | 270,000 | – | |
| 19 | AKTS AKTIS ONCOLOGY INC | 1.9% | $17.2m | 960,847 | – | ||
| 20 | CNTX CONTEXT THERAPEUTICS INC | 1.5% | $13.8m | 5,250,000 | – | ||
| 21 | DTIL PRECISION BIOSCIENCES INC | 1.4% | $12.3m | 2,236,732 | – | ||
| 22 | DBVT DBV TECHNOLOGIES S A | 1.3% | $12.0m | 574,200 | – | ||
| 23 | UNCY UNICYCIVE THERAPEUTICS INC | 0.7% | $6.6m | 1,000,000 | – | ||
| 24 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.7% | $6.4m | 719,000 | – | ||
| 25 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.7% | $6.3m | 1,100,000 | – | |
| 26 | PHVS PHARVARIS N V | Healthcare | 0.5% | $4.7m | 165,000 | – | |
| 27 | CATX PERSPECTIVE THERAPEUTICS INC | 0.4% | $3.3m | 791,555 | – | ||
| 28 | EVMN EVOMMUNE INC | 0.4% | $3.3m | 143,472 | – | ||
| 29 | GOSS GOSSAMER BIO INC | Healthcare | 0.3% | $2.5m | 7,750,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.